| Literature DB >> 25680884 |
M Carrington Reid1, Christopher Eccleston2, Karl Pillemer3.
Abstract
Entities:
Mesh:
Year: 2015 PMID: 25680884 PMCID: PMC4707527 DOI: 10.1136/bmj.h532
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Standardized tools for pain assessment
| Measure (No of items) | Domains assessed |
|---|---|
| Multidimensional measures: | |
| Brief pain inventory-short form (n=9)w1 | Sensory (intensity, location); pain related interference or disability; treatments, degree of relief provided by treatments; affect |
| Geriatric pain measure (n=24)w2 | Sensory (intensity, temporal pattern); pain related interference or disability; affect |
| Pain disability index (n=7)w3 | Pain related interference or disability |
| Short-form McGill pain questionnaire (n=15)w4 | Sensory; exacerbating or ameliorating factors; affect |
| PROMIS* pain interference, behavior, intensity itemsw5 | Pain related interference or disability; pain behaviors; pain intensity |
| WOMAC (n=24)w6 | Sensory (intensity); pain related interference or disability; joint stiffness |
| Roland Morris disability questionnaire† (n=24)w7 | Pain related interference or disability; affect |
| Unidimensional measures: | |
| Numeric rating scale (n=1)w8 | Sensory (intensity) |
| Verbal rating scale (n=1)w9 | Sensory (severity) |
| Visual analog scale (n=1)w9 | Sensory (intensity) |
| Faces pain scale (n=1)w10 | Sensory (intensity) |
| LANSS pain scale (n=7)w11 | Sensory (assessment of possible neuropathic pain) |
| DN4 (n=4)w12 | Sensory (assessment of possible neuropathic pain) |
WOMAC=Western Ontario and McMaster Universities osteoarthritis index; LANSS=Leeds assessment of neuropathic symptoms and signs; DN4=Douleur Neuropathique 4 questions.
*Available in long and short form versions: long version for pain interference has 40 items; there are five short form versions for pain interference where the number of questions varies from 4 to 8; long form version for pain behavior has 39 items, short form version has 7. PROMIS pain intensity measure has three items.
†Originally developed as tool to measure perceived disability in patients with back pain. Increasingly used to measure perceived disability due to pain from any cause.
Guideline recommendations for drug management of chronic pain
| Analgesic class | Recommendation* | Safety concerns | Quality of evidence† |
|---|---|---|---|
| Paracetamol (acetaminophen) | Use for mild to moderate pain | Liver toxicity a concern at higher doses, particularly from unintentional overdose | High |
| Oral NSAIDs | Use for shortest time possible; may be appropriate when other treatments have failed | Selective and non-selective NSAIDs associated with adverse gastrointestinal, renal, and cardiovascular side effects | High |
| Topical NSAIDs | Use as alternative to oral NSAIDs, particularly when pain is localized | Safety of topical NSAIDs in patients receiving anticoagulation or with renal impairment remains unknown | Moderate |
| Tramadol | Consider for use in patients who do not respond to paracetamol/NSAIDs | Increased risk of seizures or serotonin syndrome when used with antidepressants; side effect profile similar to that of opioids | Not reported |
| Opioids | Use for moderate to severe pain or with substantial impairments in functioning or quality of life and when other treatments have been unsuccessful | Side effects limit use (constipation, sedation, nausea) | Low |
| Tricyclic antidepressants | Avoid tertiary tricyclics (for example, amitriptyline) because of concerns over adverse side effects; consider trial of secondary amine (nortriptyline) for neuropathic pain | Side effects limit use, electrocardiographic monitoring required owing to risk of QTc prolongation; serum level monitoring also recommended | Moderate |
| Anticonvulsants (for example, pregabalin, gabapentin) | Use for neuropathic pain | Side effects limit use (for example, sedation, peripheral edema); dose adjustment necessary in those with renal impairment | Moderate |
NSAIDs=non-steroidal anti-inflammatory drugs.
*Recommendations present in both UK and US guidelines.2 3
†Quality of evidence ratings are from the 2009 American Geriatrics Society guideline.